苯达莫司汀、来那度胺和地塞米松(BRd)方案作为复发难治多发性骨髓瘤二线治疗具有高活性——一项II期试验
这项前瞻性多中心II期研究评估BRd方案(苯达莫司汀、来那度胺、地塞米松)用于仅接受过一线治疗的复发难治多发性骨髓瘤患者。50例入组,中位年龄68.5岁,45例可评估患者中23例(51%)达到完全缓解或非常好的部分缓解。4级中性粒细胞减少和血小板减少分别发生于17例(34%)和8例(16%)。
要点
- BRd方案在仅一线治疗后复发的多发性骨髓瘤中,45例可评估患者中23例(51%)达CR/VGPR。
- 4级中性粒细胞减少发生于17例(34%),4级血小板减少发生于8例(16%)。
- 研究达到主要终点:诱导治疗后CR/VGPR率>40%。
核心结论
- BRd是复发难治多发性骨髓瘤二线治疗安全有效的方案,可使相当比例患者获得高质量缓解。
研究设计与样本
- 前瞻性、多中心II期研究,纳入仅接受过一线治疗的复发难治多发性骨髓瘤患者50例,中位年龄68.5岁(范围46-83岁)。
- 治疗方案:苯达莫司汀75 mg/m2第1、2天;来那度胺25 mg第1-21天;地塞米松(40/20 mg)第1、8、15、22天,共6个28天诱导周期,随后来那度胺联合地塞米松单药治疗12个周期。
- 根据方案定义的标准给予聚乙二醇非格司亭。
主要发现
- 45例可评估患者中,23例(51%)达到完全缓解或非常好的部分缓解。
- 4级中性粒细胞减少发生于17例(34%),4级血小板减少发生于8例(16%)。
关键数值与推荐
- 研究主要终点为诱导治疗后完全缓解/非常好的部分缓解率>40%,实际45例可评估患者中23例(51%)达到CR/VGPR。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The combination of lenalidomide (Revlimid® , R) and dexamethasone (d) is a standard regimen for patients with relapsed/refractory multiple myeloma (rrMM). With this regimen, only a small fraction of patients will achieve high quality responses [≥ very good partial response (VGPR)]. The combination of bendamustine (B), lenalidomide and dexamethasone (BRd) has shown high efficacy in patients with advanced rrMM. However, dose-limiting haematotoxicity restricted its use in extensively pre-treated patient populations. This prospective, multicentre Phase II study evaluated the efficacy and safety of BRd in rrMM patients with one prior line of therapy. Fifty patients were enrolled (median age 68·5 years [range 46-83]) and were treated with B 75 mg/m2 days 1, 2; R 25 mg days 1-21 and d (40/20 mg) days 1, 8, 15 and 22, for 6 28-day induction cycles, followed by 12 cycles with Rd alone. Pegfilgrastim was administered according to protocol-defined criteria. The study aimed to demonstrate a complete response (CR)/VGPR rate of >40% after induction therapy. Of 45 evaluable patients, 23 (51%) achieved a CR/VGPR. Grade 4 neutropenia or thrombocytopenia occurred in 17 (34%) and 8 (16%) of patients, respectively. BRd is a safe and efficacious regimen as a second line treatment for rrMM, leading to high quality responses in a considerable proportion of patients.
引用
- Mey UJ, Brugger W, Schwarb H, et al. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br J Haematol. 2016. PMID: 27983764. doi:10.1111/bjh.14481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。